Ciencias de la vida
MAGNETIC ALIGNMENT OF INTRALUMINAL SENSING DEVICE IN CONNECTOR AND ASSOCIATED DEVICES, SYSTEMS, AND METHODS
22/01/2026 -
A system includes an intravascular guidewire and a connector. The intravascular guidewire includes a flexible elongate member, a sensor, and a guidewire electrical contact. The connector is a...
NOVEL COMPOUND FOR INHIBITING NAMPT, AND COMPOSITION INCLUDING SAME
22/01/2026 -
The present invention relates to a novel compound for inhibiting nicotinamide phosphoribosyl transferase (NamPT), a composition including the same, and various uses thereof.
N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE
22/01/2026 -
The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The...
COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS
22/01/2026 -
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which...
TUMOR MICROENVIRONMENT-ACTIVATED CYTOKINE AND USE THEREOF
22/01/2026 -
A tumor microenvironment-activated cytokine interferon-alpha (IFNα) is prepared by mutating IFNα. After cysteine mutation of IFN-α, IFN-α is joined to a substrate and a mask body that can be...
TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN
22/01/2026 -
The invention provides melflufen, or a salt thereof, or a pharmaceutical formulation comprising melflufen, or a salt thereof, for use in the treatment and/or prophylaxis of immunoglobulin light...
TREATMENT AGENT FOR LUNG ADENOCARCINOMAS
22/01/2026 -
Provided are: a therapeutic agent for NK2 homeobox 1 (NKX2-1)-negative lung adenocarcinoma containing a Porcupine inhibitor as an active component; a NKX2-1-negative lung adenocarcinoma organoid;...
Inhibitors of MENIN-MLL Interaction
22/01/2026 -
The present invention is directed to the compounds 101 and 102—inhibitors of the interaction of menin and MLL. The inhibitors described herein can be useful in the treatment of diseases or...
Cannabinoid Powder With High Specific Surface Area
22/01/2026 -
A crystalline cannabinoid powder includes cannabinoid crystal particles having a cannabinoid purity of at least 95% by weight and a Specific Surface Area (SSA) of at least 0.7 m2/g. A crystalline...
COMPOSITIONS FOR TREATING COLITIS AND/OR PREVENTING COLON CANCER
22/01/2026 -
Compositions comprising a plurality of live Lactococcus lacticlactis bacteria and one or more compounds selected from δ-tocotrienol (δTE), γ-tocotrienol (γTE), and/or...
IMAGE PROCESSING DEVICE, IMAGE PROCESSING SYSTEM, IMAGE DISPLAY METHOD, AND IMAGE PROCESSING PROGRAM
22/01/2026 -
An image processing device receives a calibration operation of adjusting a viewpoint when a three-dimensional image obtained by imaging a three-dimensional structure of a biological tissue based...
Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies
22/01/2026 -
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-4 receptor (hIL-4R). The formulations may contain, in addition...
MOTION COMPENSATION DEVICE
22/01/2026 -
Proposed is a motion compensation device including an overtube configured to be inserted into a human body and reach a target object that is a surgical target, and a compensation computation part...
FOOD PRODUCT INCLUDING VIABLE CELLS OF LACTIC ACID BACTERIA, METHOD FOR PRODUCING SAME, AND METHOD FOR INHIBITING INCREASE IN ACIDITY AND/OR DECREASE IN NUMBER OF VIABLE CELLS
22/01/2026 -
A technique may suppress increase in acidity and decrease in the number of viable bacteria during storage of a food product containing a viable lactic acid bacterium, and containing a small amount...
COMPOSICIÓN FARMACÉUTICA DE VIRUS ADENOASOCIADO RECOMBINANTE
12/01/2026 -
<p>La presente invención se refiere al campo de los productos farmacéuticos, la terapia génica y la medicina, y más específicamente a composiciones farmacéuticas estables que...
N-ハロアルキル置換カンプトテシン誘導体の抗体複合薬物
16/01/2026 -
...
抗CTHRC1抗体を含む併用療法及びその使用方法
16/01/2026 -
...
N-メチレンアミドリンカーを含有する抗体-薬物複合体
16/01/2026 -
...
遺伝子操作T細胞
16/01/2026 -
...
抗EGFR/MUC1抗体及びその使用
16/01/2026 -
本開示は、抗EGFR/MUC1抗体、及びそれらに由来する抗体薬物コンジュゲート、並びにそれらの使用に関する。
Actividades asistenciales
Agroalimentación
Automoción y nueva movilidad
Energía sostenible y eficiente
Materiales avanzados
Medio ambiente y sostenibilidad
Patrimonio natural y cultural
Procesos productivos e industria 4.0
Química y biotecnología
Salud y calidad de vida
Transformación digital



